R&D channel feed – Endpoints News

R&D channel feed

With Ph3 data, Pfizer wants to have the ‘first and only’ RSV vaccine to cover adults as young as 18 years old

Last year

AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24

Last year

Novo further boosts evidence for semaglutide’s heart benefits beyond weight loss: #ACC24

Last year

Alnylam’s RNAi therapy passes second Phase 2 hypertension test, with third underway: #ACC24

Last year

Arrowhead reports full Phase 2b data for lipid drug, but Ionis is a step ahead: #ACC24

Last year

Ionis presents pivotal rare disease data, builds toward first solo launch: #ACC24

Last year

Bristol Myers touts long-term efficacy of recently acquired Karuna drug

Last year

AstraZeneca unveils positive Phase 3 data to move Imfinzi into earlier stages of lung cancer

Last year

‘Look before you leap’: Caribou to start Ph1 autoimmune study of CAR-T therapy

Last year

Novartis plots new Pluvicto filing timeline after waiting for overall survival results

Last year

eFFECTOR's lead lung cancer program falls through, stock crashes

Last year

CureVac releases mixed interim Phase 2 data for seasonal flu vaccine

Last year

Exclusive: Jim Wilson startup gets FDA green light for first test of gene editing in babies

Last year

Academic trial suggests modest GLP-1 effect in Parkinson's disease, but questions remain

Last year

Merck KGaA inks ADC discovery deal with AI techbio worth up to $1.4B in milestones

Last year

LENZ plans NDA submission for presbyopia eye drops this year, looks to launch in 2025

Last year

FibroGen eyes rebound path with Ph1 ADC data for prostate cancer drug

Last year

Alterome raises $132M to take next-gen cancer drugs aimed at the 'undruggable' into clinic

Last year

Additional drugmakers flag risks of working with WuXi amid heightened US scrutiny

Last year

Gritstone's Phase 2 cancer vaccine trial misses the mark, stock spirals down

Last year

Verve pauses lead base editing program after safety event, switches focus to follow-up candidate near clinic

Last year

Roivant announces study win in eye disease for Pfizer asset, plans $1.5B share buyback

Last year

Carisma to lay off staff, drop clinical CAR-M program in favor of second candidate

Last year

Disc Medicine blames 'outsized' placebo response on mixed Phase 2 data in rare blood disorder

Last year

First page Previous page 49 50 515253 54 55 Next page Last page